Evidence map›Paper›PMID 31464859›Full record

Trial reportSexually transmitted diseases2019

Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women.

Mariam El-Zein, Agnihotram V Ramanakumar, Paulo Naud, Cecilia M Roteli-Martins, Newton S de Carvalho, Paola Colares de Borba, Julio C Teixeira, Anna-Barbara Moscicki, Diane M Harper, Stephen K Tyring and 4 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Sexually transmitted diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00120848 phase2completednot on this map

Study of the Efficacy of Candidate HPV 16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Adolescent & Young Adult Women in North America and Brazil Vaccinated in Primary Study 580299/001

TypeinterventionalSponsorGlaxoSmithKlineRan2003 to 2007Enrolled776ConditionsInfections, PapillomavirusArmsHPV 16/18 VLP AS04
NCT00689741 phase2completednot on this map

A Double-blind, Placebo-controlled, Randomised Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil.

TypeinterventionalSponsorGlaxoSmithKlineRan2001 to 2003Enrolled1,113ConditionsInfections, PapillomavirusArmsCervarix, placebo
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Sexually Transmitted Diseases among Saudi Women: Knowledge and Misconceptions.International journal of environmental research and public health · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mariam El-ZeinFrom the Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
Agnihotram V RamanakumarFrom the Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
Paulo NaudFederal University of Rio Grande do Sul-UFRGS/HCPA, Hospital de Clínicas de Porto Alegre, Porto Alegre.
Cecilia M Roteli-MartinsLeonor Mendes de Barros Hospital-Secretaria da Saude de São Paulo, São Paulo.
Newton S de CarvalhoDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics Infectious Diseases Sector, Federal University of Parana, Curitiba, Parana.
Paola Colares de BorbaInstituto de Prevenção do Câncer, Fortaleza.
Julio C TeixeiraDepartment of Gynecology and Obstetrics, Oncology Division-CAISM, State University of Campinas, Campinas, Brazil.
Anna-Barbara MoscickiUniversity of California, Division of Adolescent Medicine, San Francisco, CA.
Diane M HarperDepartment of Obstetrics and Gynecology and Community and Family Medicine, Geisel Medical School at Dartmouth, Norris Cotton Cancer Center, Hanover, NH.
Stephen K TyringDepartments of Microbiology/Molecular Genetics, Dermatology & Internal.
Brian RamjattanFirst Line Medical Services Ltd., St. John's, Newfoundland and Labrador, Canada.
Gary DubinTakeda Pharmaceuticals, Zurich, Switzerland.
Eduardo L FrancoFrom the Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
HPV-007 Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlobal variation in human papillomavirus (HPV) prevalence and persistence may be explained by differences in risk factors, such as sexual activity, oral contraceptive use, and behavioral factors. We evaluated determinants of acquisition and clearance of HPV infection among young women previously unexposed to HPV.

methodsFive hundred thirty-four women aged 15 to 25 years who were cytology and HPV DNA negative, and seronegative for anti-HPV-16/18 antibodies, were recruited (July 2000-September 2001) from study centers in Brazil, the United States, and Canada (NCT00689741/NCT00120848). They were followed up for 76 months. Cervical samples were HPV genotyped via polymerase chain reaction. We used multivariable (forward stepwise, P = 0.15) Cox proportional hazards regression to estimate rate ratios (RR) and 95% confidence intervals (CI), separately according to length of follow-up time.

resultsOn short-term follow-up (0-27 months), 257 (48%; 8535.80 person-months; incidence rate = 30.11; 95% CI, 26.64-34.02) incident HPV infections were detected. Marital status, lifetime number of sex partners, history of any sexually transmitted disease, and occasional use of oral contraceptives were strongly associated with acquisition of any HPV. Having 2 or more lifetime sex partners (RR, 2.03; 95% CI, 1.37-3.02) and a history of any sexually transmitted disease (RR, 1.98; 95% CI, 1.19-3.29) were the most important determinants of high-risk HPV (hrHPV) incidence. During the entire follow-up (0-76 months), an increased hrHPV clearance was found among women in North America (RR, 1.38; 95% CI, 1.08-1.78) and black women (RR, 1.64; 95% CI, 1.04-2.60). Greater number of lifetime partners was associated with reduced clearance rates for any HPV (RR, 0.65; 95% CI, 0.43-0.98).

conclusionsWe identified variation in risk of HPV acquisition and clearance among women unexposed to HPV at baseline.

Indexed as

AdolescentAdultBrazilCanadaCervix UteriCohort StudiesDouble-Blind MethodFemaleGenotypeHumansIncidencePapillomaviridaePapillomavirus InfectionsPrevalenceRisk FactorsSexual Behavior

Identifiers

PMID31464859
PMCPMC6887628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.